BioSpace News Archive

From the rising trend of royalty financing to other adaptive funding strategies, firms think outside the box in responding to unprecedented challenges.

Medable Inc. announces new intelligent automation technology applied across its clinical trials platform to cut standard trial build timelines by at least half.

Premier Research and BioCentriq have entered a strategic partnership to revolutionize the pre-Investigational New Drug process and accelerate the clinical translation of novel cell therapy products.

Jubilant Therapeutics Inc today announced preliminary safety, pharmacokinetic and initial efficacy results of of the Phase I trial in advanced cancer patients.

Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced the initiation of enrollment for its Phase 1 clinical trial of FT825 / ONO-8250, a multiplexed-engineered, chimeric antigen receptor (CAR) T-cell product candidate targeting human epidermal growth factor receptor 2 (HER2).

Bionano Genomics, Inc. reported certain unaudited preliminary financial and commercial highlights for the fourth quarter and fiscal year ended December 31, 2023.

Pasithea Therapeutics Corp. announced the invention of a crystalline form of PAS-004 which is captured in polymorph and stereoisomer patent filings that when issued we believe will extend patent protection to at least 2045.

Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today announced certain preliminary, unaudited results for the fourth quarter and full year ended December 31, 2023, and provided its initial full year 2024 guidance.

OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the 42nd Annual J.P. Morgan Healthcare Conference, being held January 8-11, 2024 at Westin St. Francis hotel in San Francisco.

Wave Life Sciences Ltd. announced key 2024 milestones across its clinical programs, growing pipeline, and leading RNA medicines platform.